Researchers have introduced a groundbreaking recurrence prediction value (RPV) system for stage II colon cancer, offering a precise way to identify patients at high risk of cancer recurrence. Using a vast international dataset, they established that RPV successfully stratifies patients into low and high-risk categories. Patients with high RPV demonstrated significantly increased risk of recurrence. This innovative approach provides an invaluable tool to guide treatment and monitoring for individuals with stage II colon cancer, potentially enhancing survival outcomes globally.
Journal Article by Mizuno S, Shigeta K (…) Kunitake H et 26 al. in Ann Surg
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.